SRRK Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Scholar Rock Holding Corp (SRRK) is a good buy for a beginner investor with a long-term investment horizon and $50,000-$100,000 available for investment. Despite short-term price fluctuations, the company's strong analyst support, positive progress on its flagship drug apitegromab, and significant cash reserves make it a promising long-term investment.
The technical indicators suggest a neutral trend. The MACD histogram is negative and contracting, RSI is neutral at 53.496, and moving averages are converging. The stock is trading near its pivot level of 45.507, with support at 42.985 and resistance at 48.028. Short-term price movement is uncertain, but no significant bearish signals are present.
Analysts have consistently raised price targets, with a range of $53-$70, and maintain Buy or Overweight ratings.
Positive progress on apitegromab's FDA review and resubmission timeline, with potential for a 2026 launch.
Strong cash reserves of $368 million to support operations and drug development.
Multiblockbuster potential for apitegromab in spinal muscular atrophy.
The company has no revenue and operates at a loss, with a Q4 net loss of $91 million.
Short-term market sentiment is slightly negative, with a pre-market price drop of -3.29%.
Broader market conditions are weak, with the S&P 500 down -1.04%.
Scholar Rock reported no revenue in Q4 2025 but improved its net income by 36.88% YoY to -$91 million. EPS also improved by 22.95% YoY to -$0.88. The company has a strong cash position of $368 million, providing a solid financial runway for its drug development and operational needs.
Analysts are overwhelmingly positive on SRRK, with multiple firms raising price targets and maintaining Buy or Overweight ratings. The consensus highlights confidence in apitegromab's approval and launch timeline, as well as its blockbuster potential in treating spinal muscular atrophy.
